Education
About Us
Working with TipRanks
Follow Us
Arcellx, Inc. (ACLX)
NASDAQ:ACLX
ACLX Stock Chart & Stats
$114.50
-$3.36(-4.36%)
At close: 4:00 PM EST
$114.50
-$3.36(-4.36%)
Day’s Range― - ―
52-Week Range$47.86 - $114.80
Previous CloseN/A
Volume227.93K
Average Volume (3M)3.23M
Market Cap
$6.70B
Enterprise Value$6.71B
Total Cash (Recent Filing)$450.33M
Total Debt (Recent Filing)$96.26M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding58,479,813
10 Day Avg. Volume5,074,216
30 Day Avg. Volume3,233,786
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)9.12
Price to Sales (P/S)164.73
P/FCF Ratio-17.27
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue300.88
Enterprise Value/Gross Profit-464.27
Enterprise Value/Ebitda-33.87
Forecast
1Y Price Target
$112.85Price Target Upside-1.44% Downside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-3.59
Revenue Forecast (FY)$81.89M
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation And Label Expansion PotentialThe therapy's favorable safety and efficacy profile driven by its D-domain binder reduces neurotoxicity risk relative to competitors and supports potential label expansion into earlier treatment lines.
Manufacturing And Commercial ExecutionGilead's established cell therapy manufacturing and commercial network should improve manufacturing reliability and launch execution, enhancing the therapy's ability to reach more patients.
Strategic Validation And Deal PremiumAnalyst views the acquisition offer and prior collaboration as strong strategic validation for the lead therapy, and the offer premium supports the view that the transaction provides fair value to shareholders.
Bears Say
Contingent Payment And Payout UncertaintyA meaningful portion of the deal's consideration is contingent on achieving ambitious cumulative sales milestones, creating uncertainty about shareholders realizing the full additional payout.
Deal Termination And Governance RiskThe agreement contains a material adverse effect clause and transfers control of manufacturing and commercialization to the buyer, which could allow the acquirer to alter or abandon the deal if regulatory, clinical, or commercial setbacks arise.
Limited Upside From Takeover PricingAnalyst notes the acquisition price effectively sets the market value for the stock and limits further upside for existing shareholders, prompting more conservative ratings.
Arcellx Inc News
ACLX FAQ
What was Arcellx, Inc.’s price range in the past 12 months?
Arcellx, Inc. lowest stock price was $47.86 and its highest was $114.80 in the past 12 months.
What is Arcellx, Inc.’s market cap?
Arcellx, Inc.’s market cap is $6.70B.
When is Arcellx, Inc.’s upcoming earnings report date?
Arcellx, Inc.’s upcoming earnings report date is May 07, 2026 which is in 57 days.
How were Arcellx, Inc.’s earnings last quarter?
Arcellx, Inc. released its earnings results on Feb 26, 2026. The company reported -$1.003 earnings per share for the quarter, beating the consensus estimate of -$1.054 by $0.051.
Is Arcellx, Inc. overvalued?
According to Wall Street analysts Arcellx, Inc.’s price is currently Overvalued.
Does Arcellx, Inc. pay dividends?
Arcellx, Inc. does not currently pay dividends.
What is Arcellx, Inc.’s EPS estimate?
Arcellx, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arcellx, Inc. have?
Arcellx, Inc. has 58,479,813 shares outstanding.
What happened to Arcellx, Inc.’s price movement after its last earnings report?
Arcellx, Inc. reported an EPS of -$1.003 in its last earnings report, beating expectations of -$1.054. Following the earnings report the stock price went up 0.105%.
Which hedge fund is a major shareholder of Arcellx, Inc.?
Currently, no hedge funds are holding shares in ACLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcellx Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$112.85 (-1.44% Downside)
$112.85 (-1.44% Downside)
Blogger Sentiment
Bullish
ACLX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.86%
12-Months-Change
Fundamentals
Return on Equity
-55.42%
Trailing 12-Months
Asset Growth
-15.09%
Trailing 12-Months
Company Description
Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
ACLX Stock 12 Month Forecast
Average Price Target
$112.85
▼(-1.44% Downside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Immunovant
―
Beam Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---